

5. Podzolkov VI, Vargina TS, Pokrovskaya AE, Safronova TA, Abramova AA. Mantle Cell Lymphoma Case Report. *Case Rep Oncol*. 2018 Dec 4;11(3):814-821. doi: 10.1159/000492665. PMID: 30627097; PMCID: PMC6323362.
6. Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. *Histopathology*. 2013 Jan;62(2):334-42. doi: 10.1111/his.12009. PMID: 23240716.
7. ATM gene deletion in patients with adult acute lymphoblastic leukemia , Mohammad A. Haidar Ph.D., Hagop Kantarjian M.D., Taghi Manshouri M.S., Chin-Yung Chang M.D., Susan O'Brien M.D., Emil Freireich M.D., Michael Keating M.D., Maher Albitar M.D. Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. *Oncotarget*. 2016 Sep 6;7(36):58638-58648. doi: 10.18632/oncotarget.10716. PMID: 27449094; PMCID: PMC5295458.
- 8) Holdener SL, Harrington L, Nguyen J, Horna P, Sagatys E, Shah B, Zhang L. Therapy-related B lymphoblastic leukemia with t(4;11)(q21;q23)/AF4-MLL in a patient with mantle cell lymphoma after recent aggressive chemotherapy: a unique case report. *Int J Clin Exp Pathol*. 2014 Mar 15;7(4):1800-4. PMID: 24817983; PMCID: PMC4014267.
- 9) Lynch DT, Koya S, Kumar A. Mantle Cell Lymphoma. [Updated 2023 Jul 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK536985/>
- 10) Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. *Blood*. 1997 Mar 15;89(6):2067-78.
- 11) Geisler CH, Kolstad A, Laurell A, Rätty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E., Nordic Lymphoma Group. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). *Blood*. 2010 Feb 25;115(8):1530-3.